Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Staging, Work-up and Management of High Risk Cutaneous Squamous Cell Carcinoma
Description
The management of high-risk cutaneous squamous cell carcinoma (cSCC) requires a multi-disciplinary approach, emphasizing the role of dermatologists in patient advocacy and coordination of care. Surgical management is the cornerstone for achieving high cure rates; Mohs surgery is recommended, especially for aggressive tumors, where wider margins are crucial to reduce recurrence risk. Radiation therapy is indicated for cases with perineural invasion, incompletely resected tumors, or lymph node involvement, as it has been shown to improve survival rates in specific situations. Systemic therapies, particularly PD-1 inhibitors like cemiplimab and pembrolizumab, are employed in advanced cases where surgery or radiation is not feasible. Neoadjuvant therapies are showing promise in enhancing surgical outcomes through improved pathological responses. Prophylactic treatments, such as nicotinamide and acitretin, alongside regular follow-up for monitoring recurrence, are essential components of patient management, as up to 80% of high-risk patients may recur within two years. Close communication with oncologists about the unique risks and characteristics of each patient is vital for effective treatment and follow-up.
View moreConclusions
- Dermatologists play a crucial role in managing high-risk cutaneous squamous cell carcinoma (cSCC) and serve as advocates for their patients.
- Achieving negative surgical margins during excision is critical for high cure rates, especially for high-risk tumors.
- Mohs micrographic surgery offers the best surgical cure rates but may require collaboration with head and neck surgeons for complex cases.
- Adjuvant radiation therapy is recommended for patients with extensive perineural invasion, multiple nerve involvement, or positive margins.
- Radiation therapy should not be the primary treatment for high-risk cSCC due to increased recurrence rates without prior surgical intervention.
- Emerging immunotherapies, such as PD-1 inhibitors, show significant promise in improving survival in patients with advanced or metastatic cSCC.
- Preventive measures, including Nicotinamide and topical therapies like 5-FU, can effectively reduce the risk of new cSCC development.
- Regular clinical follow-up and imaging are necessary due to the high rates of recurrence in cSCC patients.
- Ruiz et al. JAMA Derm 2019
- Wang et al. Head Neck 2012
- Veness et al. Laryngoscope 2005
- Harris et al. JAMA Otolaryngol Head and Neck Surg 2018
- Ruiz et al. JAAD 2020
- Sapir et al. Radiother Onc. 2016
- Harris et al. JAMA Otolaryngol Head and Neck 2019
- Barrios et al. J Am Acad Dermatol. 2020 November; 83(5): 1239-1253.
- Migden et al. NEJM 2018
- Hughes et al. Ann Oncol 2021; Grob et al. J Clin Oncol 2020
- Gross et al. Lancet Oncol 2023; Gross et al. NEJM 2022
- Chen et al. NEJM 2015; Badri et al. 2021 Dermatologic Surgery
- Massey et al. JAMA Dermatol. 2021
- Jansen et al. NEJM 2019